Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma
Open Access
- 3 April 2020
- Vol. 12 (4), 872
- https://doi.org/10.3390/cancers12040872
Abstract
There is a need to improve the effectiveness of radiotherapy (RT) in hepatocellular carcinoma (HCC). Therefore, the purpose of this study was to explore the efficacy and toxicity of the anti-microtubule agent Vinorelbine as a radiosensitizer in HCC. The radio sensitivity of 16 HCC patient-derived xenograft (PDX) models was determined by quantifying the survival fraction following irradiation in vitro, and Vinorelbine radio sensitization was determined by clonogenic assay. Ectopic HCC xenografts were treated with a single dose of 8 Gy irradiation and twice-weekly 3 mg/kg Vinorelbine. Tumor growth and changes in the proteins involved in DNA repair, angiogenesis, tumor cell proliferation, and survival were assessed, and the 3/16 (18.75%), 7/16 (43.75%), and 6/16 (37.5%) HCC lines were classified as sensitive, moderately sensitive, and resistant, respectively. The combination of RT and Vinorelbine significantly inhibited tumor growth, DNA repair proteins, angiogenesis, and cell proliferation, and promoted more apoptosis compared with RT or Vinorelbine treatment alone. Vinorelbine improved HCC tumor response to standard irradiation with no increase in toxicity. HCC is prevalent in less developed parts of the world and is mostly unresectable on presentation. Vinorelbine and conventional radiotherapy are cost-effective, well-established modalities of cancer treatment that are readily available. Therefore, this strategy can potentially address an unmet clinical need, warranting further investigation in early-phase clinical trials.Funding Information
- National Research Foundation Singapore (NRF-CRP17-2017-05)
This publication has 43 references indexed in Scilit:
- Gastroduodenal Complications After Concurrent Chemoradiation Therapy in Patients With Hepatocellular Carcinoma: Endoscopic Findings and Risk FactorsInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinomaLiver International, 2010
- The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular CarcinomaOncology, 2010
- Accelerated treatment using intensity‐modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinomaCancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Xenografts of Human Hepatocellular Carcinoma: A Useful Model for Testing DrugsClinical Cancer Research, 2006
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- Vinorelbine: cell cycle kinetics and differential sensitivity of human lymphocyte subpopulationsToxicology Letters, 1997